Advertisement
Advances in Pediatrics

Advances in Hemophilia A Management

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Peyvandi F.
        • Garagiola I.
        • Young G.
        The past and future of haemophilia: diagnosis, treatments, and its complications.
        Lancet. 2016; 388: 187-197
        • Chavin S.I.
        Factor VIII: structure and function in blood clotting.
        Am J Hematol. 1984; 16: 297-306
        • Schieve L.A.
        • Byams V.R.
        • Dupervil B.
        • et al.
        Evaluation of CDC's hemophilia surveillance program - universal data collection (1998-2011) and community counts (2011-2019), United States.
        MMWR Surveill Summ. 2020; 69: 1-18
        • Soucie J.M.
        • Evatt B.
        • Jackson D.
        Occurrence of hemophilia in the United States. the hemophilia surveillance system project investigators.
        Am J Hematol. 1998; 59: 288-294
        • Plug I.
        • Mauser-Bunschoten E.P.
        • Brocker-Vriends A.H.
        • et al.
        Bleeding in carriers of hemophilia.
        Blood. 2006; 108: 52-56
        • Bryant P.
        • Boukouvala A.
        • McDaniel J.
        • et al.
        Hemophilia A in females: considerations for clinical management.
        Acta Haematol. 2020; 143 (d): 289-294
        • National Hemophilia Foundation
        MASAC document 264 - MASAC recommendations regarding diagnosis and management of inherited bleeding disorders in girls and women with personal and family history of bleeding.
        (Available at:) (Accessed September 15, 2021)
        • Blanchette V.S.
        • Key N.S.
        • Ljung L.R.
        • et al.
        Definitions in hemophilia: communication from the SSC of the ISTH.
        J Thromb Haemost. 2014; 12: 1935-1939
        • Israels S.
        • Schwetz N.
        • Boyar R.
        • et al.
        Bleeding disorders: characterization, dental considerations and management.
        J Can Dent Assoc. 2006; 72: 827
        • Srivastava A.
        • Santagostino E.
        • Dougall A.
        • et al.
        WFH guidelines for the management of hemophilia, 3rd edition.
        Haemophilia. 2020; 26: 1-158
        • Manco-Johnson M.J.
        • Abshire T.C.
        • Shapiro A.D.
        • et al.
        Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
        N Engl J Med. 2007; 357: 535-544
        • Bolton-Maggs P.H.
        Optimal haemophilia care versus the reality.
        Br J Haematol. 2006; 132: 671-682
        • Berntorp E.
        • Boulyjenkov V.
        • Brettler D.
        • et al.
        Modern treatment of haemophilia.
        Bull World Health Organ. 1995; 73: 691-701
        • Dunkley S.
        • Lam J.C.M.
        • John M.J.
        • et al.
        Principles of haemophilia care: the Asia-Pacific perspective.
        Haemophilia. 2018; 24: 366-375
        • Soucie J.M.
        • Nuss R.
        • Evatt B.
        • et al.
        Mortality among males with hemophilia: relations with source of medical care. the hemophilia surveillance system project investigators.
        Blood. 2000; 96: 437-442
        • Moorehead P.C.
        • Chan A.K.C.
        • Lemyre B.
        • et al.
        A practical guide to the management of the fetus and newborn with hemophilia.
        Clin Appl Thromb Hemost. 2018; 24: 29S-41S
        • National Hemophilia Foundation
        MASAC document 221 - recommendations on administration of vaccines to individuals with bleeding disorders.
        (Available at) (Accessed September 17, 2021)
        • Passeri E.V.
        • Martinelli M.
        • Gatteri V.
        • et al.
        Standard and water rehabilitation: An analysis of over 14 years' experience in patients with haemophilia or other clotting factor disorders after orthopaedic surgery.
        Haemophilia. 2019; 25: 699-707
        • Kargarfard M.
        • Dehghadani M.
        • Ghias R.
        The effect of aquatic exercise therapy on muscle strength and joint's range of motion in hemophilia patients.
        Int J Prev Med. 2013; 4: 50-56
        • Scully C.
        • Diz Dios P.
        • Giangrande P.
        Oral care for people with hemophilia or a hereditary bleeding tendency.
        2nd edition. World Federation of Hemophilia, 2008 (Available at:) (Accessed September 18, 2021)
        • Kalsi H.
        • Nanayakkara L.
        • Pasi K.J.
        • et al.
        Access to primary dental care for patients with inherited bleeding disorders.
        Haemophilia. 2012; 18: 510-515
        • Anderson J.A.
        • Brewer A.
        • Creagh D.
        • et al.
        Guidance on the dental management of patients with haemophilia and congenital bleeding disorders.
        Br Dent J. 2013; 215: 497-504
        • Eyster M.E.
        • Asaad S.M.
        • Gold B.D.
        • et al.
        Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs.
        Haemophilia. 2007; 13: 279-286
        • Rattray B.
        • Nugent D.J.
        • Young G.
        Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia.
        Haemophilia. 2006; 12: 514-517
        • Tsoukas C.
        • Eyster M.E.
        • Shingo S.
        • et al.
        Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
        Blood. 2006; 107: 1785-1790
        • Escobar M.A.
        • Brewer A.
        • Caviglia H.
        • et al.
        Recommendations on multidisciplinary management of elective surgery in people with haemophilia.
        Haemophilia. 2018; 24: 693-702
        • Mannucci P.M.
        Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.
        Blood. 1997; 90: 2515-2521
        • Batty P.
        • Austin S.K.
        • Khair K.
        • et al.
        Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.
        Br J Haematol. 2017; 176: 796-804
        • Oldenburg J.
        Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.
        Blood. 2015; 125: 2038-2044
        • Astermark J.
        • Petrini P.
        • Tengborn L.
        • et al.
        Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.
        Br J Haematol. 1999; 105: 1109-1113
        • Warren B.B.
        • Thornhill D.
        • Stein J.
        • et al.
        Young adult outcomes of childhood prophylaxis for severe hemophilia a: results of the joint outcome continuation study.
        Blood Adv. 2020; 4: 2451-2459
        • Kurnik K.
        • Bidlingmaier C.
        • Engl W.
        • et al.
        New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
        Haemophilia. 2010; 16: 256-262
        • Gouw S.C.
        • van der Bom J.G.
        • Marijke van den Berg H.
        Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: the CANAL cohort study.
        Blood. 2007; 109: 4648-4654
        • Gouw S.C.
        • van den Berg H.M.
        • Fischer K.
        • et al.
        Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia a: the RODIN study.
        Blood. 2013; 121: 4046-4055
        • National Hemophilia Foundation
        Products licensed in the US.
        (Available at) (Accessed August 2, 2021)
        • Graf L.
        Extended half-life factor VIII and factor IX preparations.
        Transfus Med Hemother. 2018; 45: 86-91
        • Berntorp E.
        • Negrier C.
        • Gozzi P.
        • et al.
        Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
        Haemophilia. 2016; 22: 389-396
        • Konkle B.A.
        • Shapiro A.D.
        • Quon D.V.
        • et al.
        BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A.
        N Engl J Med. 2020; 383: 1018-1027
        • Walsh C.E.
        • Soucie J.M.
        • Miller C.H.
        • et al.
        Impact of inhibitors on hemophilia A mortality in the United States.
        Am J Hematol. 2015; 90: 400-405
        • D'Angiolella L.S.
        • Cortesi P.A.
        • Rocino A.
        • et al.
        The socioeconomic burden of patients affected by hemophilia with inhibitors.
        Eur J Haematol. 2018; 101: 435-456
        • Wight J.
        • Paisley S.
        The epidemiology of inhibitors in haemophilia A: a systematic review.
        Haemophilia. 2003; 9: 418-435
        • Verbruggen B.
        • van Heerde W.L.
        • Laros-van Gorkom B.A.
        Improvements in factor VIII inhibitor detection: from bethesda to nijmegen.
        Semin Thromb Hemost. 2009; 35: 752-759
        • de Moerloose P.
        • Fischer K.
        • Lambert T.
        • et al.
        Recommendations for assessment, monitoring and follow-up of patients with haemophilia.
        Haemophilia. 2012; 18: 319-325
        • Young G.
        How I treat children with haemophilia and inhibitors.
        Br J Haematol. 2019; 186: 400-408
        • Brackmann H.H.
        • White 2nd, G.C.
        • Berntorp E.
        • et al.
        Immune tolerance induction: what have we learned over time?.
        Haemophilia. 2018; 24: 3-14
        • Valentino L.A.
        • Kempton C.L.
        • Kruse-Jarres R.
        • et al.
        US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.
        Haemophilia. 2015; 21: 559-567
        • Kempton C.L.
        • White 2nd, G.C.
        How we treat a hemophilia A patient with a factor VIII inhibitor.
        Blood. 2009; 113: 11-17
        • Astermark J.
        • Donfield S.M.
        • DiMichele D.M.
        • et al.
        A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
        Blood. 2007; 109: 546-551
        • Leissinger C.
        • Gringeri A.
        • Antmen B.
        • et al.
        Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
        N Engl J Med. 2011; 365: 1684-1692
        • Kitazawa T.
        • Igawa T.
        • Sampei Z.
        • et al.
        A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
        Nat Med. 2012; 18: 1570-1574https://doi.org/10.1038/nm.2942
        • National Hemophilia Foundation
        MASAC document 258 - Recommendation on the use and management of emicizumab-kxwh (hemlibra®) for hemophilia A with and without inhibitors.
        (Available at) (Accessed August 20, 2021)
        • Lenting P.J.
        • Denis C.V.
        • Christophe O.D.
        Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?.
        Blood. 2017; 130: 2463-2468
        • Oldenburg J.
        • Mahlangu J.N.
        • Kim B.
        • et al.
        Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
        N Engl J Med. 2017; 377: 809-818
        • Oldenburg J.
        • Mahlangu J.N.
        • Bujan W.
        • et al.
        The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
        Haemophilia. 2019; 25: 33-44
        • Pipe S.W.
        • Shima M.
        • Lehle M.
        • et al.
        Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
        Lancet Haematol. 2019; 6: e295-e305
        • Young G.
        • Liesner R.
        • Chang T.
        • et al.
        A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
        Blood. 2019; 134: 2127-2138
        • Gundabolu K.
        • Goldsweig A.
        • Bhatt V.R.
        • et al.
        ST-segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII.
        Haemophilia. 2020; 26: e5-e8
        • Seaman C.D.
        • Ragni M.V.
        Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.
        Blood Adv. 2017; 1: 1309-1311
        • Le Quellec S.
        • Negrier C.
        Emicizumab should be prescribed independent of immune tolerance induction.
        Blood Adv. 2018; 2: 2783-2786
        • Nathwani A.C.
        Gene therapy for hemophilia.
        Hematology Am Soc Hematol Educ Program. 2019; 2019: 1-8
        • Perrin G.Q.
        • Herzog R.W.
        • Markusic D.M.
        Update on clinical gene therapy for hemophilia.
        Blood. 2019; 133: 407-414
        • Sidonio Jr., R.F.
        • Pipe S.W.
        • Callaghan M.U.
        • et al.
        Discussing investigational AAV gene therapy with hemophilia patients: a guide.
        Blood Rev. 2021; 47: 100759
        • Anguela X.M.
        • High K.A.
        Entering the modern era of gene therapy.
        Annu Rev Med. 2019; 70: 273-288
        • Brunetti-Pierri N.
        • Ng P.
        Adenoviral vectors for hemophilia gene therapy.
        J Genet Syndr Gene Ther. 2013; 2: 017
        • High K.A.
        • Roncarolo M.G.
        Gene Therapy.
        N Engl J Med. 2019; 381: 455-464
        • Rangarajan S.
        • Walsh L.
        • Lester W.
        • et al.
        AAV5-factor VIII gene transfer in severe hemophilia A.
        N Engl J Med. 2017; 377: 2519-2530
        • Pasi K.J.
        • Rangarajan S.
        • Mitchell N.
        • et al.
        Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A.
        N Engl J Med. 2020; 382: 29-40
        • George L.A.
        • Monahan P.E.
        • Eyster M.E.
        • et al.
        Phase I/II trial of SPK-8011: stable and durable FVIII expression after AAV gene transfer for hemophilia A [abstract].
        Res Pract Thromb Haemost. 2021; 5 (Available at)
        • von Drygalski A.
        • Young G.
        Recent advances in gene therapy for hemophilia clinical trials.
        (Available at) (Accessed November 15, 2021)
        • Manno C.S.
        • Pierce G.F.
        • Arruda V.R.
        • et al.
        Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
        Nat Med. 2006; 12: 342-347
        • Nathwani A.C.
        • Reiss U.
        • Tuddenham E.
        • et al.
        Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer.
        Blood. 2018; 132: 491
        • Donsante A.
        • Miller D.G.
        • Li Y.
        • et al.
        AAV vector integration sites in mouse hepatocellular carcinoma.
        Science. 2007; 317: 477